Rigvir Group is looking for partners globally

To finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

Arrow Down Icon

Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine (RIGVIR®) is looking for partners globally to finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

We have elaborated a registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the following:

  • Medical need – currently no treatment solutions for both early Melanoma and Uveal Melanoma;
  • Target market value exceeds 4.5 Billion EUR annually;
  • Company owns a unique and well-established treatment method;
  • Company owns a GMP API production and know-how;
  • RIGVIR® has Excellent safety profile;
  • New projects are supported by preclinical data and retrospective clinical observations;
  • The production and use of ECHO7 virus RIGVIR® have granted strong international IP protection;
  • The Company has authorization to start any Phase II clinical trials in the EU.

It is expected that the company value would rise 3 times within the next two years but in 5 to 7 years period – 10 times, at least.


Information Request

Click the Icon to Learn More About Our Organisation

Our Company

Everything you need to know about Rigvir Group.

Products

Discover our manufacturing and product approach.

Science

Learn how we face scientific challenges.

Partnerships

Find out more about the opportunities of sharing skills and success.

Recent News

Access the latest information regarding our company, people, science, partnerships and opportunities.

Explore

Clinical studies from 1968

First genetically non-modified virus

One of the fastest growing biotech companies of the Northern Europe

Proven in clinical practice for more than 10 years

Contact the Investor Relations Team

Information Request